The Indian Institute of Integrative Medicine (IIIM), the Indian Council of Medical Research (ICMR), and Sami Labs Limited, Sabinsa's sister company, have entered into a tripartite agreement whereby Sami and Sabinsa acquired two Indian patents pertaining to pterocarpus marsupium, an existing ingredient in the Sabinsa global product portfolio .
Dr. Majeed spoke on Curcumin first, and highlighted the following:
By the scientific and clinical evidence that is being received currently, the year 2014 is going to be the year of Curcumin C3 Complex. This is the time to decide how we, as an industry, are going to handle the expansion of consumer demand for Curcumin, which will have a significant impact on how large the market grows and the longevity of that market. Quite simply, we want to ensure that consumers are using products that work, consistently.
IIIM, based in Jam.mu, India, one of the oldest institutions of the Council of Scientific and Industrial Research (CSIR), was established in 1957 and dedicated to advanced research on the isolation and standardization of drugs from natural products useful against various diseases. Under a sponsored project from ICMR on the isolation of novel compounds from pterocarpus marsupium for blood sugar management, two novel compounds were isolated which showed significant activity in that area.
The intellectual property created and filed for both the compounds by carrying out original research in the field of drug discovery for the past several decades resulted in the two Indian patents Sami / Sabinsa have licensed, which are entitled: